Carl Icahn Calls Pfizer/Allergan Deal a 'Travesty' - NY Times Op-Ed
Get Alerts PFE Hot Sheet
Join SI Premium – FREE
The Pfizer (NYSE: PFE)/Allergan (NYSE: AGN) deal is a "travesty", Carl Icahn said in a New York Times Op-Ed piece:
"THE Pfizer-Allergan deal is a travesty. Pfizer, which is based in New York, will move overseas by merging with Allergan, based in Ireland, in a maneuver known as a corporate inversion. The point isn’t to find corporate synergy. It is to leave behind our uncompetitive international tax system.
Not only is this the largest inversion in history, but it will also open the floodgates for other companies to leave the United States, further eroding our tax base, damaging our economy and costing many thousands of jobs"
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mavis acquires Pep Boys from Icahn Enterprises for $700M
- D.E. Shaw owns $1B+ stake in Sysco - Reuters
- Virtu Financial said to explore $3.5B sales of brokerage unit
Create E-mail Alert Related Categories
Hedge Funds, Insiders' Blog, Mergers and AcquisitionsRelated Entities
Carl IcahnSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share